Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marylore Chenel

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
Clinical Pharmacology and Therapeutics|December 7, 2020
Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case StudyJennifer Lang, Ludwig Vincent, Marylore Chenel, et al.
Drug Discovery Today|May 5, 2023
Virtual patients, digital twins and causal disease models: Paving the ground for in silico clinical trialsPhilippe Moingeon, Marylore Chenel, Cécile Rousseau, et al.
The AAPS Journal|October 9, 2020
Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation MethodJennifer Lang, Ludwig Vincent, Marylore Chenel, et al.
Journal of Pharmaceutical Sciences|November 7, 2003
Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in ratsSandrine Marchand, Marylore Chenel, Isabelle Lamarche, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 14, 2021
Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactionsJennifer Lang, Ludwig Vincent, Marylore Chenel, et al.
The AAPS Journal|January 14, 2016
Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: a Novel Method to Handle the Interval Censoring Caused by Measurement of Smaller TumorsPhilippe B Pierrillas, Michel Tod, Magali Amiel, et al.
The AAPS Journal|May 28, 2011
Development of a complex parent-metabolite joint population pharmacokinetic modelJulie Bertrand, Céline M Laffont, France Mentré, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 30, 2009
Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithmJulie Bertrand, Emmanuelle Comets, Céline M Laffont, et al.
The AAPS Journal|June 23, 2016
Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: Handling Sacrifice Censoring and Error Caused by Experimental Measurement on Larger Tumor SizesPhilippe B Pierrillas, Michel Tod, Magali Amiel, et al.
Journal of Pharmacokinetics and Pharmacodynamics|December 13, 2005
Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trialMarylore Chenel, Kayode Ogungbenro, Vincent Duval, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Clinical Pharmacology and Therapeutics|December 7, 2020
Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case StudyJennifer Lang, Ludwig Vincent, Marylore Chenel, et al.
Drug Discovery Today|May 5, 2023
Virtual patients, digital twins and causal disease models: Paving the ground for in silico clinical trialsPhilippe Moingeon, Marylore Chenel, Cécile Rousseau, et al.
The AAPS Journal|October 9, 2020
Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation MethodJennifer Lang, Ludwig Vincent, Marylore Chenel, et al.
Journal of Pharmaceutical Sciences|November 7, 2003
Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in ratsSandrine Marchand, Marylore Chenel, Isabelle Lamarche, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 14, 2021
Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactionsJennifer Lang, Ludwig Vincent, Marylore Chenel, et al.
The AAPS Journal|January 14, 2016
Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: a Novel Method to Handle the Interval Censoring Caused by Measurement of Smaller TumorsPhilippe B Pierrillas, Michel Tod, Magali Amiel, et al.
The AAPS Journal|May 28, 2011
Development of a complex parent-metabolite joint population pharmacokinetic modelJulie Bertrand, Céline M Laffont, France Mentré, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 30, 2009
Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithmJulie Bertrand, Emmanuelle Comets, Céline M Laffont, et al.
The AAPS Journal|June 23, 2016
Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: Handling Sacrifice Censoring and Error Caused by Experimental Measurement on Larger Tumor SizesPhilippe B Pierrillas, Michel Tod, Magali Amiel, et al.
Journal of Pharmacokinetics and Pharmacodynamics|December 13, 2005
Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trialMarylore Chenel, Kayode Ogungbenro, Vincent Duval, et al.
Pageof 6